The genetic basis of variability in drug response is at the core of pharmacogenomics (PGx) studies, aiming at reducing adverse drug reaction (ADR), which have interethnic variability. This study used the Kardiovize Brno 2030 random urban Czech sample population to analyze polymorphisms in a wide spectrum of genes coding for liver enzymes involved in drug metabolism. We aimed at correlating real life drug consumption with pharmacogenomic profile, and at comparing these data with the SUPER-Finland Finnish PGx database. A total of 250 individuals representative of the Kardiovize Brno 2030 cohort were included in an observational study. Blood DNA was extracted and 59 single nucleotide polymorphisms within 13 genes (BCHE, CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A5, F2, F5, IFNL3, SLCO1B1, TPMT, UGT1A1, VKORC1), associated to different drug metabolizing rates, were characterized by genotyping using a genome wide commercial array. Widely used drugs such as anti-coagulant warfarin and lipid lowering agent atorvastatin were associated to an alarmingly high percentage of users with intermediate/poor metabolism for them. Significant differences in the frequency of normal/intermediate/poor/ultrarapid/rapid metabolizers were observed for CYPD26 (p<0.001), CYP2C19 (p<0.001) and UGT1A1 (p<0.001) between the Czech and the Finnish study populations. Our study demonstrated that administration of some popular drugs to a Czech random sample population is associated with different drug metabolizing rates and therefore exposing to risk for ADRs. We also highlight interethnic differentiation of some common pharmacogenetics variants between Central (Czech) and North European (Finnish) population studies, suggesting the utility of PGx-informed prescription based on variant genotyping.

Department of Stem Cell Biology and Transplantology Research Institute of the Medical University of Varna Varna Bulgaria

Harvard T H Chan School of Public Health Harvard University Cambridge MA United States of America

Institute for Molecular Medicine Finland HiLIFE University of Helsinki Helsinki Finland

Institute of Biomedicine University of Turku Turku Finland

International Clinical Research Center St Anne's University Hospital Brno Czech Republic

Liverpool Centre for Cardiovascular Sciences Liverpool John Moores University Liverpool United Kingdom

Liverpool Centre for Cardiovascular Sciences University of Liverpool Liverpool United Kingdom

Stanley Center for Psychiatric Research The Broad Institute of MIT and Harvard University Cambridge MA United States of America

See more in PubMed

Serretti A, Artioli P. The pharmacogenomics of selective serotonin reuptake inhibitors. Pharmacogenomics J. 2004;4(4):233–44. doi: 10.1038/sj.tpj.6500250 PubMed DOI

Bonham VL, Callier SL, Royal CD. Will Precision Medicine Move Us beyond Race? N Engl J Med. 2016;374(21):2003–5. doi: 10.1056/NEJMp1511294 PubMed DOI PMC

Pinto N, Dolan ME. Clinically relevant genetic variations in drug metabolizing enzymes. Curr Drug Metab. 2011;12(5):487–97. doi: 10.2174/138920011795495321 PubMed DOI PMC

Davies EC, Green CF, Mottram DR, Pirmohamed M. Interpreting adverse drug reaction (ADR) reports as hospital patient safety incidents. Br J Clin Pharmacol. 2010;70(1):102–8. doi: 10.1111/j.1365-2125.2010.03671.x PubMed DOI PMC

Movsisyan NK, Vinciguerra M, Lopez-Jimenez F, Kunzová Š, Homolka M, Jaresova J, et al.. Kardiovize Brno 2030, a prospective cardiovascular health study in Central Europe: Methods, baseline findings and future directions. Eur J Prev Cardiol. 2018;25(1):54–64. doi: 10.1177/2047487317726623 PubMed DOI

Buzková H, Pechandová K, Slanar O, Perlík F. Frequency of single nucleotide polymorphisms of CYP2D6 in the Czech population. Cell Biochem Funct. 2008;26(1):76–81. doi: 10.1002/cbf.1402 PubMed DOI

Geisler T, Schaeffeler E, Dippon J, Winter S, Buse V, Bischofs C, et al.. CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation. Pharmacogenomics. 2008;9(9):1251–9. doi: 10.2217/14622416.9.9.1251 PubMed DOI

Hočevar K, Maver A, Peterlin B. Actionable Pharmacogenetic Variation in the Slovenian Genomic Database. Front Pharmacol. 2019;10:240. doi: 10.3389/fphar.2019.00240 PubMed DOI PMC

Justenhoven C, Hamann U, Pierl CB, Baisch C, Harth V, Rabstein S, et al.. CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009;115(2):391–6. doi: 10.1007/s10549-008-0076-4 PubMed DOI

Rideg O, Háber A, Botz L, Szücs F, Várnai R, Miseta A, et al.. Pilot study for the characterization of pharmacogenetically relevant CYP2D6, CYP2C19 and ABCB1 gene polymorphisms in the Hungarian population. Cell Biochem Funct. 2011;29(7):562–8. doi: 10.1002/cbf.1788 PubMed DOI

Skrętkowicz J, Barańska M, Kaczorowska A, Rychlik-Sych M. Genetic polymorphisms of CYP2D6 oxidation in patients with systemic lupus erythematosus. Arch Med Sci. 2011;7(5):864–9. doi: 10.5114/aoms.2011.25563 PubMed DOI PMC

Häkkinen K, Kiiski JI, Lähteenvuo M, Jukuri T, Suokas K, Niemi-Pynttäri J, et al.. Implementation of CYP2D6 copy-number imputation panel and frequency of key pharmacogenetic variants in Finnish individuals with a psychotic disorder. Pharmacogenomics J. 2022;22(3):166–72. doi: 10.1038/s41397-022-00270-y PubMed DOI PMC

Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. Journal of biomedical informatics. 2009;42(2):377–81. doi: 10.1016/j.jbi.2008.08.010 PubMed DOI PMC

Graffelman J. Exploring diallelic genetic markers: the HardyWeinberg package. Journal of Statistical Software. 2015;64:1–23.

Relling M, Gardner E, Sandborn W, Schmiegelow K, Pui CH, Yee S, et al.. Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clinical Pharmacology & Therapeutics. 2011;89(3):387–91. doi: 10.1038/clpt.2010.320 PubMed DOI PMC

Mizzi C, Dalabira E, Kumuthini J, Dzimiri N, Balogh I, Başak N, et al.. A European Spectrum of Pharmacogenomic Biomarkers: Implications for Clinical Pharmacogenomics. PLoS One. 2016;11(9):e0162866. doi: 10.1371/journal.pone.0162866 PubMed DOI PMC

Böhm R, Cascorbi I. Pharmacogenetics and Predictive Testing of Drug Hypersensitivity Reactions. Front Pharmacol. 2016;7:396. doi: 10.3389/fphar.2016.00396 PubMed DOI PMC

Campion DP, Dowell FJ. Translating Pharmacogenetics and Pharmacogenomics to the Clinic: Progress in Human and Veterinary Medicine. Front Vet Sci. 2019;6:22. doi: 10.3389/fvets.2019.00022 PubMed DOI PMC

Jorgensen AL, FitzGerald RJ, Oyee J, Pirmohamed M, Williamson PR. Influence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysis. PLoS One. 2012;7(8):e44064. doi: 10.1371/journal.pone.0044064 PubMed DOI PMC

Gage BF, Bass AR, Lin H, Woller SC, Stevens SM, Al-Hammadi N, et al.. Effect of Genotype-Guided Warfarin Dosing on Clinical Events and Anticoagulation Control Among Patients Undergoing Hip or Knee Arthroplasty: The GIFT Randomized Clinical Trial. Jama. 2017;318(12):1115–24. doi: 10.1001/jama.2017.11469 PubMed DOI PMC

Abudahab S, Hakooz N, Tobeh N, Gogazeh E, Gharaibeh M, Al-Eitan L, et al.. Variability of CYP2C8 polymorphisms in three Jordanian populations: Circassians, Chechens and Jordanian-Arabs. Journal of Immigrant and Minority Health. 2022;24(5):1167–76. doi: 10.1007/s10903-021-01264-x PubMed DOI

Al-Eitan LN, Rababa’h DM, Hakooz NM, Alghamdi MA, Dajani RB. Analysis of Comprehensive Pharmacogenomic Profiling of VIP Variants Among the Genetically Isolated Chechen Subpopulation from Jordan. Pharmacogenomics and Personalized Medicine. 2020:199–215. doi: 10.2147/PGPM.S254677 PubMed DOI PMC

Argentati C, Tortorella I, Bazzucchi M, Emiliani C, Morena F, Martino S. The other side of Alzheimer’s disease: Influence of metabolic disorder features for novel diagnostic biomarkers. Journal of Personalized Medicine. 2020;10(3):115. doi: 10.3390/jpm10030115 PubMed DOI PMC

AL-Eitan LN, Al-Maqableh HW, Mohammad NN, Khair Hakooz NM, Dajani RB. Genetic Analysis of Pharmacogenomic VIP Variants of ABCB1, VDR and TPMT Genes in an Ethnically Isolated Population from the North Caucasus Living in Jordan. Current Drug Metabolism. 2020;21(4):307–17. doi: 10.2174/1389200221666200505081139 PubMed DOI

Jarvis JP, Peter AP, Shaman JA. Consequences of CYP2D6 copy-number variation for pharmacogenomics in psychiatry. Frontiers in Psychiatry. 2019;10:432. doi: 10.3389/fpsyt.2019.00432 PubMed DOI PMC

Lee S-J. Clinical application of CYP2C19 pharmacogenetics toward more personalized medicine. Frontiers in genetics. 2013;3:318. doi: 10.3389/fgene.2012.00318 PubMed DOI PMC

Gammal R. Court MH, Haidar CE, Iwuchukwu OF, Gaur AH, Alvarellos M, et al.. Clinical pharmacogenetics implementation consortium (CPIC) guideline for UGT1A1 and atazanavir prescribing. Clin Pharmacol Ther. 2016;99(4):363–9. doi: 10.1002/cpt.269 PubMed DOI PMC

Wright GEB, Carleton B, Hayden MR, Ross CJD. The global spectrum of protein-coding pharmacogenomic diversity. Pharmacogenomics J. 2018;18(1):187–95. doi: 10.1038/tpj.2016.77 PubMed DOI PMC

Schärfe CPI, Tremmel R, Schwab M, Kohlbacher O, Marks DS. Genetic variation in human drug-related genes. Genome Med. 2017;9(1):117. doi: 10.1186/s13073-017-0502-5 PubMed DOI PMC

Zhou Y, Ingelman-Sundberg M, Lauschke VM. Worldwide Distribution of Cytochrome P450 Alleles: A Meta-analysis of Population-scale Sequencing Projects. Clin Pharmacol Ther. 2017;102(4):688–700. doi: 10.1002/cpt.690 PubMed DOI PMC

Pietarinen P, Tornio A, Niemi M. High Frequency of CYP2D6 Ultrarapid Metabolizer Genotype in the Finnish Population. Basic Clin Pharmacol Toxicol. 2016;119(3):291–6. doi: 10.1111/bcpt.12590 PubMed DOI

Arias-de la Torre J, Vilagut G, Ronaldson A, Serrano-Blanco A, Martín V, Peters M, et al.. Prevalence and variability of current depressive disorder in 27 European countries: a population-based study. Lancet Public Health. 2021;6(10):e729–e38. doi: 10.1016/S2468-2667(21)00047-5 PubMed DOI PMC

Jukic MM, Smith RL, Haslemo T, Molden E, Ingelman-Sundberg M. Effect of CYP2D6 genotype on exposure and efficacy of risperidone and aripiprazole: a retrospective, cohort study. Lancet Psychiatry. 2019;6(5):418–26. doi: 10.1016/S2215-0366(19)30088-4 PubMed DOI

Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alföldi J, Wang Q, et al.. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature. 2020;581(7809):434–43. doi: 10.1038/s41586-020-2308-7 PubMed DOI PMC

Ait Ouakrim D, Pizot C, Boniol M, Malvezzi M, Boniol M, Negri E, et al.. Trends in colorectal cancer mortality in Europe: retrospective analysis of the WHO mortality database. Bmj. 2015;351:h4970. doi: 10.1136/bmj.h4970 PubMed DOI PMC

Kunzova S, Maugeri A, Medina-Inojosa J, Lopez-Jimenez F, Vinciguerra M, Marques-Vidal P. Determinants of Metabolic Health Across Body Mass Index Categories in Central Europe: A Comparison Between Swiss and Czech Populations. Front Public Health. 2020;8:108. doi: 10.3389/fpubh.2020.00108 PubMed DOI PMC

Movsisyan NK, Vinciguerra M, Medina-Inojosa JR, Lopez-Jimenez F. Cardiovascular Diseases in Central and Eastern Europe: A Call for More Surveillance and Evidence-Based Health Promotion. Ann Glob Health. 2020;86(1):21. doi: 10.5334/aogh.2713 PubMed DOI PMC

Karanikolos M, Adany R, McKee M. The epidemiological transition in Eastern and Western Europe: a historic natural experiment. Eur J Public Health. 2017;27(suppl_4):4–8. doi: 10.1093/eurpub/ckx158 PubMed DOI

Allebeck P. The prevention paradox or the inequality paradox? Eur J Public Health. 2008;18(3):215. doi: 10.1093/eurpub/ckn048 PubMed DOI